Postępy Dermatologii i Alergologii

Full text

4/2026 vol. 43
Review paper

Short-term risk and long-term incidence rate of herpes zoster with upadacitinib in patients with atopic dermatitis and psoriatic arthritis: a systematic review and meta-analysis

Zhimin Wang 1
,
Lu Xue 1
,
Quan Zhou 1
,
Huiying Li 1
,
Shangyi Meng 1
,
Huiping Wang 1

  1. Department of Dermatovenereology, Tianjin Medical University General Hospital/Tianjin Institute of Sexually Transmitted Disease, Tianjin, China

Adv Dermatol Allergol 2026; XLIII (4): 345-354

DOI: https://doi.org/10.5114/ada.2026.164292
Data publikacji online: 2026/09/14
Article file
PDiA Short term.pdf
  1. Kaaz K, Szepietowski J C, Matusiak £. Sleep quality among adult patients with chronic dermatoses. Adv Dermatol Allergol 2019; 36: 659-66.
  2. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017; 16: 843-62.
  3. Kamata M, Tada Y. Optimal use of jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence. JID Innov 2023; 3: 100195.
  4. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391: 2503-12.
  5. Mcinnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 2021; 384: 1227-39.
  6. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2021; 157: 1047-55.
  7. Boneschansker L, Ananthakrishnan AN; Massachusetts General Hospital Crohn’s And Colitis Center Collaborators. Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real-world data. Clin Gastroenterol Hepatol 2023; 21: 2427-9.e1.
  8. Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for crohn’s disease. N Engl J Med 2023; 388: 1966-80.
  9. van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108-17.
  10. Lim DZJ, Tey HL, Salada BMA, et al. Herpes zoster and post-herpetic neuralgia – diagnosis, treatment, and vaccination strategies. Pathogens 2024; 13: 596.
  11. Cohen EJ, Jeng BH. Herpes zoster: a brief definitive review. Cornea 2021; 40: 943-9.
  12. Manzar D, Nair N, Suntres E, et al. Systematic review and network meta-analysis of the risk of herpes zoster with biological therapies and selective janus kinase-1 inhibitors in atopic dermatitis. Adv Dermatol Allergol 2024; 41: 72-7.
  13. Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-84.
  14. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet 2021; 397: 2151-68.
  15. Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2021; 397: 2169-81.
  16. Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis. JAAD Int 2021; 6: 27-36.
  17. Gooderham M, Torres T, Imafuku S, et al. Efficacy and safety of upadacitinib dose escalation and reduction in adults with moderate-to-severe atopic dermatitis: results of a randomized blinded treat-to-target multicenter phase IIIb/IV study (flex up). Br J Dermatol 2025; 193: 1101-11.
  18. McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 2021; 384: 1227-39.
  19. Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2021; 80: 312-20.
  20. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol 2022; 158: 404-13.
  21. Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD up study results. J Allergy Clin Immunol 2022; 149: 977-87.
  22. Katoh N, Ohya Y, Murota H, et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: 2-year interim results from the phase 3 rising up study. Dermatol Ther 2023; 13: 221-34.
  23. Katoh N, Ikeda M, Ohya Y, et al. Safety and efficacy of upadacitinib for atopic dermatitis in Japan: analysis of the 3-year phase 3 rising up study. Dermatol Ther 2024; 14: 213-32.
  24. Irvine AD, Prajapati VH, Guttman-Yassky E, et al. Efficacy and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results through 140 weeks. Am J Clin Dermatol 2025; 26: 1003-16.
  25. McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open 2021; 7: e001838.
  26. Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study. Rheumatol Ther 2021; 8: 903-19.
  27. McInnes IB, Kato K, Magrey M, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatol Ther 2023; 10: 275-92.
  28. Mease P, Setty A, Papp K, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study. Clin Exp Rheumatol 2023 ; 41: 2286-97.
  29. Muddebihal A, Khurana A, Sardana K. JAK inhibitors in dermatology: the road travelled and path ahead, a narrative review. Exp Rev Clin Pharmacol 2023; 16: 279-95.
  30. Yamaoka K, Oku K. JAK inhibitors in rheumatology. Immunol Med 2023; 46: 143-52.
  31. Sunzini F, Mcinnes I, Siebert S. JAK inhibitors and infections risk: Focus on herpes zoster. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20936059.
  32. Moodley D, Yoshida H, Mostafavi S, et al. Network pharmacology of JAK inhibitors. Proc Natl Acad Sci USA 2016; 113: 9852-7.
  33. Galloway J, Raine T, Rivett L, et al. Herpes zoster and janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clin Exp Rheumatol 2022; 40: 1432-41.
  34. Johnson RW, Alvarez-Pasquin M J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 2015; 3: 109-20.
  35. Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clinic Proc 2017; 92: 1806-21.
  36. Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses 2022; 14: 192.
  37. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57: 1431-8.
  38. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in auto-immune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 2016; 68: 2328-37.
  39. Gialouri CG, Moustafa S, Thomas K, et al. Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: A systematic review of clinical trials and real-world studies. Rheumatol Int 2023; 43: 421-35.
  40. Chai R, Li X, Shen W, et al. Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Front Immunol 2025; 16: 1586792.
  41. Xu Q, He L, Yin Y. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol 2023; 14: 1241954.
  42. Wu SE, Chen YH, Chung CH, et al. Atopic dermatitis as a risk factor for herpes zoster infection independent of treatment: a nationwide population-based cohort study. Dermatitis 2023; 34: 241-9.
  43. Chovatiya R, Silverberg JI. Association of herpes zoster and chronic inflammatory skin disease in United States inpatients. J Am Acad Dermatol 2021; 85: 1437-45.
  44. Burmester GR, Deodhar A, Irvine AD, et al. Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease. Adv Ther 2025; 42: 5215-37.
  45. Yoon S, Kim K, Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2024; 38: 52-61.
  46. Zhang C, Fu Z, Liu J, et al. Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis. Front Pharmacol 2025; 16: 1598972.
  47. Narbutt J, ¯uber Z, Lesiak A, et al. Vaccinations in selected immune-related diseases treated with biological drugs and JAK inhibitors – literature review and statement of experts from Polish Dermatological Society. Vaccines 2024; 12: 82.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications